 |
|
|
|
 |
|
|
| Article 1 to 10 out of 20 concerning Sanofi-aventis Groupe
|
-
Global Vaccine Market Forecast to 2012
(09 Oct 2008)
Examine This Global Vaccine Market Forecast to 2012 as the Market is Expected to Emerge as the Fastest Growing Therapy Area in the Next 5 Years
Research and Markets has announced the addition of the "Global Vaccine Market Forecast to 2012" report to their offering."Global Vaccine Market Forecast to 2012”, our new research report, states that vaccines, which were earlier thought as a low ...
-
Sanofi-aventis announces the termination of development and commercialization agreement for S-1 with Taiho Pharmaceutical
(22 Jul 2008)
Sanofi-aventis announced that it is returning its territory rights to Taiho Pharmaceutical Co., Ltd. Japan for the development and commercialization of the oral anticancer agent S-1.This termination follows the announcement by Taiho Pharmaceutical ...
-
Sanofi-aventis and Oxford Biomedica report encouraging TroVax Phase II results in metastatic renal cancer
(04 Jun 2008)
Sanofi-aventis and Oxford BioMedica announced encouraging updated results from Phase II trials of TroVax in metastatic (advanced) renal cancer. TroVax is Oxford BioMedica's lead therapeutic cancer vaccine, which is being developed in metastatic ...
-
Crucell: Start of Phase II Clinical Study for Rabies Monoclonal Antibody Combination in the Philippines
(15 May 2008)
Crucell N.V. announced that its rabies monoclonal antibody combination product has entered a second phase II clinical study in the Philippines. On 31 March 2008 the company announced the start of a first phase II clinical study in the U.S.The second ...
-
Crucell Announces Start of Phase II Clinical Study Rabies Monoclonal Antibody Combination in US
(03 Apr 2008)
First Milestone Achieved in Collaboration Agreement with Sanofi Pasteur
Crucell N.V. announced that its rabies monoclonal antibody combination has entered a Phase II clinical trial in the United States. At the beginning of the year, Crucell announced it had signed a collaboration and commercialization agreement with ...
-
First European application filed for product using intradermal microinjection system BD Soluvia
(18 Feb 2008)
Novel influenza vaccine delivered using BD's innovative technology
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, has submitted the first application in Europe to deliver a vaccine using BD Soluvia, a microinjection system developed by BD (Becton, Dickinson and Company). The submission for the first ...
-
Dyax Enters Into Antibody Agreements with Sanofi-aventis for the Fully Human Monoclonal Antibody and Phage Display Technology
(13 Feb 2008)
Dyax Retains Co-development Rights and Profit Sharing for Certain Partner Programs
Dyax Corp. and sanofi-aventis announced that they have entered into agreements in which sanofi-aventis has been granted an exclusive worldwide license for the development and commercialization of the fully human monoclonal antibody DX-2240, as well ...
-
Crucell Enters Agreement with Sanofi Pasteur for Next-generation Biologicals against Rabies
(04 Jan 2008)
Exclusive agreement for rabies monoclonal antibodies to fight fatal disease
Crucell N.V. announced that it has signed an exclusive collaboration and commercialization agreement with sanofi pasteur, the vaccines division of sanofi-aventis Group, for Crucell's rabies monoclonal antibodies, the next-generation rabies ...
-
Acambis announces global collaboration agreement with Sanofi Pasteur on leading West Nile vaccine
(15 Nov 2007)
Acambis plc announced that it has signed an exclusive global collaboration agreement with Sanofi Pasteur, the vaccines division of sanofi-aventis Group, for Acambis' ChimeriVax(TM)-West Nile vaccine. Under the terms of the agreement, Acambis will ...
-
Oxford Biomedica and Sanofi-Aventis report new TroVax Phase II trial results in renal cancer
(05 Jun 2007)
Oxford BioMedica and sanofi-aventis announced new data from two Phase II trials of TroVax® in renal cancer. TroVax® is Oxford BioMedica's lead cancer immunotherapy product, which is being developed in collaboration with sanofi-aventis. The Phase II ...
Additional information
Sanofi-aventis Groupe
Paris, France
Company
|
|
|
|
|
|
Top
